Priavoid’s PRI-101: A New Oral "Detangler" Aiming to Reverse Protein Buildup

German biotechnology company Priavoid has presented breakthrough data at the AD/PD™ 2026 conference in Copenhagen, suggesting that its experimental drug, PRI-101, could become a first-in-class disease-modifying treatment for the condition. Unlike current therapies that only manage symptoms, PRI-101 is designed to target the root cause of the condition: the buildup of toxic alpha-synuclein protein aggregates. Using a proprietary "detangler" platform, the orally available drug binds to these harmful clusters and physically breaks them apart, converting them back into harmless, non-toxic forms. This process aims to not only stop the death of nerve cells but potentially reverse the damage already done to the brain's circuitry. The preclinical results are particularly encouraging, showing that PRI-101 effectively reduces these toxic aggregates in both human brain organoids and animal models. In these studies, the treatment led to significant improvements in physical performance and even prolonged survival compared to a placebo. Crucially, researchers confirmed that the drug efficiently crosses the blood-brain barrier, reaching the substantia nigra—the area of the brain most affected by the condition—where it significantly reduced protein aggregation. With these successful "proof-of-concept" results now public, Priavoid is preparing to move PRI-101 into clinical trials with people. If successful in humans, this "detangler" approach would represent a major shift in care, moving from passive symptom management toward a future where the underlying biological drivers of the condition can be actively dismantled.